1. Impact of the Timing of Metoprolol Administration During STEMI on Infarct Size and Ventricular Function
- Author
-
Mario Nuño-Ayala, Beatriz López-Melgar, José Manuel García-Ruiz, Ana García-Álvarez, Jaime García-Prieto, Alonso Mateos, Valentin Fuster, Gonzalo J. López-Martín, José Angel Cabrera, Javier Sánchez-González, Angel Macías, Jaume Aguero, Borja Ibanez, Braulio Pérez-Asenjo, Carlos Galán-Arriola, Antonio Fernández-Ortiz, Rodrigo Fernández-Jiménez, Leticia Fernández-Friera, Gonzalo Pizarro, and Pedro Martínez-Tenorio
- Subjects
0301 basic medicine ,Male ,2013 ACCF/AHA GUIDELINE ,Emergency Medical Services ,Swine ,Enfermedad cardiovascular ,030204 cardiovascular system & hematology ,0302 clinical medicine ,Medicine ,Myocardial reperfusion ,Ventricular function ,Ventricular Remodeling ,left ventricular ejection fraction ,Middle Aged ,reperfusion injury ,Adrenergic beta-1 Receptor Antagonists ,ST-SEGMENT-ELEVATION ,myocardial infarction ,cardioprotection ,Injections, Intravenous ,cardiovascular system ,Female ,Medical emergency ,Infarto de miocardio ,Cardiology and Cardiovascular Medicine ,Administration (government) ,Metoprolol ,circulatory and respiratory physiology ,ACUTE MYOCARDIAL-INFARCTION ,Resonancia magnética nuclear (Medicina) ,PERCUTANEOUS CORONARY INTERVENTION ,Time to treatment ,Magnetic Resonance Imaging, Cine ,Myocardial Reperfusion ,cardiac magnetic resonance ,Drug Administration Schedule ,CLINICAL-TRIAL ,Time-to-Treatment ,CARDIOPROTECTION ,03 medical and health sciences ,Percutaneous Coronary Intervention ,St elevation myocardial infarction ,Animals ,Humans ,ASSOCIATION TASK-FORCE ,cardiovascular diseases ,Sistema cardiovascular ,business.industry ,BETA-BLOCKERS ,METOCARD-CNIC TRIAL ,Stroke Volume ,Infarct size ,medicine.disease ,Disease Models, Animal ,030104 developmental biology ,ST Elevation Myocardial Infarction ,ISCHEMIA/REPERFUSION ,business ,Cardiac magnetic resonance ,human activities ,Animal facility - Abstract
BACKGROUND Pre-reperfusion administration of intravenous (IV) metoprolol reduces infarct size in ST-segment elevation myocardial infarction (STEMI). OBJECTIVES This study sought to determine how this cardioprotective effect is influenced by the timing of metoprolol therapy having either a long or short metoprolol bolus-to-reperfusion interval. METHODS We performed a post hoc analysis of the METOCARD-CNIC (effect of METOprolol of CARDioproteCtioN during an acute myocardial InfarCtion) trial, which randomized anterior STEMI patients to IV metoprolol or control before mechanical reperfusion. Treated patients were divided into short-and long-interval groups, split by the median time from 15 mg metoprolol bolus to reperfusion. We also performed a controlled validation study in 51 pigs subjected to 45 min ischemia/reperfusion. Pigs were allocated to IV metoprolol with a long (-25 min) or short (-5 min) pre-perfusion interval, IV metoprolol post-reperfusion (+60 min), or IV vehicle. Cardiac magnetic resonance (CMR) was performed in the acute and chronic phases in both clinical and experimental settings. RESULTS For 218 patients (105 receiving IV metoprolol), the median time from 15 mg metoprolol bolus to reperfusion was 53 min. Compared with patients in the short-interval group, those with longer metoprolol exposure had smaller infarcts (22.9 g vs. 28.1 g; p = 0.06) and higher left ventricular ejection fraction (LVEF) (48.3\% vs. 43.9\%; p = 0.019) on day 5 CMR. These differences occurred despite total ischemic time being significantly longer in the long-interval group (214 min vs. 160 min; p < 0.001). There was no between-group difference in the time from symptom onset to metoprolol bolus. In the animal study, the long-interval group (IV metoprolol 25 min before reperfusion) had the smallest infarcts (day 7 CMR) and highest long-term LVEF (day 45 CMR). CONCLUSIONS In anterior STEMI patients undergoing primary angioplasty, the sooner IV metoprolol is administered in the course of infarction, the smaller the infarct and the higher the LVEF. These hypothesis-generating clinical data are supported by a dedicated experimental large animal study. (C) 2016 by the American College of Cardiology Foundation. The authors thank Noemi Escalera and Maite Rodriguez, who were outstanding in the management of the clinical trial and imaging analyses. The authors are also indebted to the generous dedication of time and effort to the METOCARD-CNIC trial by all coinvestigators from SUMMA112, 061 Galicia, and SAMUR. The coordinating center at SCU-SUMMA112 was crucial for the proper conduct of the trial. Tamara Cordoba, Oscar Sanz, Ruben Mota, Santiago Rodriguez, Eugenio Fernández, and the rest of the team at the CNIC Animal Facility and farm provided outstanding animal care and support. Simon Bartlett (CNIC) provided English editing. Sí
- Published
- 2016
- Full Text
- View/download PDF